Thoracic surgeon Daniela Molena leads clinical trials to improve outcomes for people with esophageal cancers.
At any time Memorial Sloan Kettering Cancer Center is conducting hundreds of clinical trials to improve care for many types of cancer. Use the tool below to browse our clinical trials that are currently enrolling new patients. Each listing explains the purpose of the trial, the trial’s eligibility criteria, and how to get more information.
The list below includes clinical trials for adult cancers. Please visit our pediatric cancer care section to find a pediatric clinical trial.
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
Prostate cancers initially need the male hormone testosterone for growth. Hormone therapies that lower the level of testosterone are among the most effective treatments for prostate cancers that have spread to other organs (metastasized). The benefits of hormone treatments do not last, however. Over time, many prostate cancers continue to grow despite hormonal therapies; these are called "castration-resistant prostate cancers" (CRPC).
Researchers are comparing mosunetuzumab to the usual treatment (rituximab) for nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL). They want to see if one drug is more effective than the other to shrink the cancer with a long-lasting response.
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
This study is assessing a blood test that may tell doctors which people need immunotherapy after bladder cancer surgery. Many types of tumors lose cells into the bloodstream and shed their DNA. This circulating tumor DNA (ctDNA) may be found before changes in a tumor can be seen on scans.
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.
Researchers are finding the best dose of ASP2138 to use in people with advanced digestive cancers. The people in this study have cancer of the pancreas, stomach (gastric cancer), or junction between the esophagus and stomach (gastroesophageal junction cancer). In addition, their cancers make a protein called CLDN 18.2 and keep growing even after treatment.
The standard treatment for high-risk locally advanced cervical cancer is chemoradiation followed by maintenance therapy. Locally advanced means the cervical cancer has spread to nearby tissue or lymph nodes. In this study, researchers want to see if adding induction therapy before chemoradiation is more effective than standard therapy.
Researchers want to find the best dose of CTIM-76 to treat advanced ovarian or endometrial cancer. The people in this study have ovarian or endometrial cancer that makes a protein called CLDN6. This protein may fuel cancer growth.
